76
|
Purcell JW, Reddy M, Davis J, Samayoa K, Vo CH, Thomsen K, Bean PA, Wood KW, Cases S. Ispinesib (SB-715992) a kinesin spindle protein (KSP) inhibitor has single agent activity and enhances the efficacy of standard-of-care therapies in pre-clinical models of breast cancer. Cancer Res 2009. [DOI: 10.1158/0008-5472.sabcs-2122] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Abstract #2122
Background: Ispinesib is a novel highly specific small molecule inhibitor of kinesin spindle protein (KSP), a motor protein that is essential for formation of a bipolar mitotic spindle and for cell cycle progression through mitosis. KSP is expressed only in proliferating cells and not in post-mitotic neurons. In preclinical models and clinical studies thus far, ispinesib exhibits a favorable safety profile compared with tubulin-targeted therapies. Ispinesib has demonstrated clinical activity in patients with locally advanced or metastatic breast cancer that failed to respond/relapsed after treatment with taxanes and anthracyclines, and is currently being evaluated in a Phase I/II trial as first-line treatment in chemotherapy-naïve patients with locally advanced (Stage IIIB) or metastatic (Stage IV) breast cancer. In the current study, we explored the anti-tumor activity of ispinesib as a single agent and in combination with approved therapies in preclinical models of breast cancer. Methods: We implanted cells representative of hormone receptor positive luminal tumors (MCF-7), tumors overexpressing Her-2 (KPL4, HCC1954, BT474) or triple-negative basal tumors (MDA-MB-468) in immunodeficient female Nude or SCID mice. We started dosing Ispinesib when tumor volume reached 100-150mm3 and monitored xenograft growth for 60 days post treatment. Results: Ispinesib administered i.p. as a single agent on a q4dx3 schedule at its MTD induced tumor regressions in all five models of human breast cancer. In particular, all treated MDA-MB-468 xenografts (7/7) were tumor free survivors at 90 days post dosing. In tumors collected at different times post-dosing, we observed a strong mitotic arrest, inhibition of proliferation, and increased apoptosis by western blotting and IHC analyses of PH3, Ki67 and cleaved PARP respectively. We also determined the efficacy of ispinesib in combination with standard-of-care therapies in breast cancer. In the Her2 overexpressing models, the combination of ispinesib and herceptin markedly improved response rate and efficacy over either single agent. Tumor Growth Inhibition (TGI) was 99% for the combined agents, 67% for herceptin and 78% for ispinesib in KPL4. A similar benefit was found by combining ispinesib with lapatinib in BT474. Finally, ispinesib enhanced the anti-tumor activity of doxorubicin, causing an increase in TGI in 2 separate models (in MCF7, TGI was 86% for the combined agents, 39% for doxorubicin and 67% for ispinesib). Additional combination studies with capecitabine are under investigation.Conclusions: In distinct models of human breast cancer, ispinesib exhibited significant anti-tumor activity as a single agent. When used in combination, ispinesib enhanced the activity of standard-of-care therapies herceptin, lapatinib and doxorubicin. These data suggest that ispinesib may offer clinical benefit in the treatment of breast cancer, and support clinical studies of ispinesib in combination with these therapies.
Citation Information: Cancer Res 2009;69(2 Suppl):Abstract nr 2122.
Collapse
|
77
|
Sreedhar B, Arundhathi R, Reddy M, Kantam M. Efficient Catalytic Activity
of Copper/Aluminum Hydrotalcite in Diaryl Ether Synthesis. SYNTHESIS-STUTTGART 2009. [DOI: 10.1055/s-0028-1083304] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
78
|
Lavé T, Parrott N, Grimm HP, Fleury A, Reddy M. Challenges and opportunities with modelling and simulation in drug discovery and drug development. Xenobiotica 2008; 37:1295-310. [PMID: 17968746 DOI: 10.1080/00498250701534885] [Citation(s) in RCA: 65] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
79
|
Sreedhar B, Reddy M, Reddy P. FeCl3/TMSCl:
An Effective Catalytic System for the Conjugate Addition of Sodium p-Toluenesulfinate to α,β-Enones. Synlett 2008. [DOI: 10.1055/s-2008-1077967] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
80
|
Varughese GI, Jammalamadaka D, Varghese AI, Babu S, Reddy M. Colchicine in acute gout: the need for a reappraisal. Int J Clin Pract 2007; 61:2132-3. [PMID: 17997813 DOI: 10.1111/j.1742-1241.2007.01419.x] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
|
81
|
Reddy R, Mutyala R, Aparoy P, Reddanna P, Reddy M. Computer Aided Drug Design Approaches to Develop Cyclooxygenase Based Novel Anti-Inflammatory and Anti-Cancer Drugs. Curr Pharm Des 2007; 13:3505-17. [DOI: 10.2174/138161207782794275] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
|
82
|
Yadav J, Reddy M, Rao P, Prasad A. Stereoselective Formal Synthesis of Crocacin C via Prins Cyclization. Synlett 2007. [DOI: 10.1055/s-2007-984896] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
83
|
Jimeno A, Chan A, Zhang X, Wheelhouse J, Solomon A, Cosenza SC, Reddy M, Rudek M, Kulesza P, Reddy E, Hidalgo M. Evaluation of ON 01910.Na, a novel modulator of polo-like kinase 1 (Plk1) pathway, and development of a cyclin-B1-based predictive assay in pancreatic cancer. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.3569] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
3569 Background: Plk1 is a key mitotic regulator of the transition through the G2/M checkpoint in the cell cycle. This work aimed to evaluate the activity of ON 01910.Na, a Plk1 pathway modulator, in in vitro and in vivo models of pancreatic cancer (PaCa) and to discover biomarkers predictive of efficacy. Methods: ON 01910.Na was tested in 12 PaCa cell lines. Studies assessing Plk1 related markers were conducted to identify biomarkers. For validation a live collection of PaCa xenografts from fresh tumor samples obtained at the time of surgical resection was used (PancXenoBank). The ex vivo assay was based on fine-needle aspirate (FNA) biopsies. Results: ON 01910.Na showed equal activity to gemcitabine against PaCa cell lines. The activity of ON 01910.Na correlated with suppression of two downstream mediators of PLK1, CDC25C and cyclin B1 (by mRNA and protein). ON 01910.Na was tested in xenografts from representative pancreatic cell lines. The selected markers were evaluated in an ex vivo assay, using intra-tumor pharmacokinetics to select the dose of the assay. Cyclin B1 mRNA evaluation yielded the most optimal combination of accuracy and reproducibility. Knockdown of cyclin B1 by siRNA had no effect per se or in the response of the resistant MiaPaca2 to either of the drugs. We next used the ex vivo assay to profile ten patient-derived cases from the PancXenoBank. Two cases were catalogued as potential responders. From each of these ten cases, a group of mice bearing at least 20 tumors received vehicle or ON 01910.Na for 28 days. There was a correlation between the ex vivo cyclin B1 assay and the sensitivity to the tested agent, as the 2 cases prospectively identified as sensitive met pre-specified criteria for response. Of the 8 tumors predicted to be resistant, only one was sensitive. In IHC testing cases showing ex vivo cyclin B1 down-regulation had also decreases in cyclin B1 protein, and there was a correlation between activity and IHC changes in cyclin B1. Conclusions: ON 01910.Na demonstrated significant activity in a preclinical model of PaCa. A rationally designed ex vivo cyclin B1-based assay not only identified cases sensitive to ON 01910.Na, but also replicated the pharmacodynamic events occurring after in vivo exposure. No significant financial relationships to disclose.
Collapse
|
84
|
Gopal K, Pradeepthi E, Gopi V, Khayum Ahammed S, Sreenivasulu Y, Reddy M, Baranwal V, Purushotham K. Occurrence, molecular diagnosis and suitable time of detection of citrus greening disease in sweet orange. ACTA ACUST UNITED AC 2007. [DOI: 10.1556/aphyt.42.2007.1.6] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
|
85
|
Sohrabi S, Navarro A, Wilson C, Sanni A, Wyrley-Birch H, Anand V, Reddy M, Rix D, Jacques B, Manas D, Talbot D. Diabetic donors as a source of non-heart-beating renal transplants. Transplant Proc 2007; 38:3402-3. [PMID: 17175285 DOI: 10.1016/j.transproceed.2006.10.079] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/19/2006] [Indexed: 11/22/2022]
Abstract
Due to the organ shortage, many renal transplantation centers attempt to increase the donor pool by using non-heart-beating donors (NHBDs). These kidneys are generally regarded as "marginal" grafts. Many centers do not consider transplantation from an NHBD with a history of diabetes as it is a more suboptimal donor. We began our NHBD program in 1998 and have performed 5 renal transplants from diabetic NHBDs. Viability testing identified kidneys suitable for single or dual transplantation. Although kidneys from brain stem dead donors with diabetes have been used successfully, our data suggested that kidneys from diabetic NHBDs can also be used although we still need long-term results.
Collapse
|
86
|
Sohrabi S, Navarro AP, Wilson C, Sanni A, Wyrley-Birch H, Anand DV, Reddy M, Rix D, Jacques B, Manas D, Talbot D. Donation after cardiac death kidneys with low severity pre-arrest acute renal failure. Am J Transplant 2007; 7:571-5. [PMID: 17352711 DOI: 10.1111/j.1600-6143.2006.01639.x] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Abstract
The widening gap between supply and demand for renal transplantation has prompted many centers to use donors after cardiac death. Some of these donors exhibit signs of acute renal failure (ARF) prior to cardiac arrest. Concern has been expressed about poor quality of graft function from such donors. In response to this perception, we reviewed 49 single renal transplant recipients from category III donors after cardiac death between 1998 and 2005, at our center. All kidneys but one had hypothermic machine perfusion and viability testing prior to transplantation. According to the RIFLE criteria, nine recipients had kidneys from donors with "low severity pre-arrest ARF". The remainder of the recipients were used as control group. There was no statistical significant difference in delayed graft function and rejection rates between these two groups. Recipients GFR at 12 months was 44.4 +/- 17.1 and 45.2 +/- 14.7 (mL/min/1.73m(2)) from donors with ARF and without ARF, respectively (p = 0.96). In conclusion, low severity ARF in kidneys from controlled after cardiac death donors can be a reversible condition after transplantation. Short-term results are comparable to the kidneys from same category donors without renal failure, providing that some form of viability assessment is implemented prior to transplantation.
Collapse
|
87
|
Navarro AP, Sohrabi S, Wilson C, Sanni A, Wyrley-Birch H, Vijayanand D, Reddy M, Rix D, Manas D, Talbot D. Renal transplants from category III non-heart-beating donors with evidence of pre-arrest acute renal failure. Transplant Proc 2007; 38:2635-6. [PMID: 17098023 DOI: 10.1016/j.transproceed.2006.08.007] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
Kidneys transplanted from non-heart-beating donors (NHBDs) have been exposed to varying degrees of ischemic damage after death. Category III donors have invariably been managed, treated, and investigated in a hospital setting prior to arrest and death. Some therefore exhibit evidence of renal dysfunction and even acute renal failure (ARF) before death. Many surgeons would regard a NHBD with pre-arrest evidence of ARF as too marginal for renal transplantation. This retrospective study examines five Maastricht category III NHBD donors with evidence of pre-arrest ARF. We compare 3- and 12-month GFR outcome data from the nine resulting transplants with 40 category III NHBD transplants with normal pre-arrest renal function. The mean GFR at 3 months was 45.4 and 43.8 for the ARF and normal group, respectively. At 12 months the GFR was 42.2 and 44.7 in the ARF and normal groups, respectively. Thus evidence of ARF pre-arrest does not preclude successful category III NHBD renal transplantation.
Collapse
|
88
|
Navarro AP, Sohrabi S, Wyrley-Birch H, Vijayanand D, Wilson C, Sanni A, Reddy M, Manas D, Rix D, Talbot D. Dual renal transplantation for kidneys from marginal non-heart-beating donors. Transplant Proc 2007; 38:2633-4. [PMID: 17098022 DOI: 10.1016/j.transproceed.2006.08.006] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
Kidneys transplanted from non-heart-beating donors (NHBD) are generally regarded as marginal or extended criteria grafts due to the associated period of warm ischemia. The most prolonged periods occurring in the category II (uncontrolled) donor. This potential for injury can adversely affect the glomular filtration rate (GFR), which in severe cases results in primary nonfunction. Viability testing can identify a group of kidneys that, although unsuitable for solitary transplantation, may be considered for dual transplant. This retrospective study examined a series of 11 dual renal transplants, comparing 3- and 12-month GFR outcome data with 81 single NHBD transplants. The mean GFR at 3 months in the dual group was 47.6 and at 12 months was 48.6. In the single group the GFR at 3 months was 40.6 and at 12 months was 41.9. Thus using viability testing to identify NHBD kidneys suitable for dual transplant appears reliable and predictable.
Collapse
|
89
|
Sohrabi S, Navarro A, Asher J, Wilson C, Sanni A, Wyrley-Birch H, Anand V, Reddy M, Rix D, Jacques B, Manas D, Talbot D. Agonal period in potential non-heart-beating donors. Transplant Proc 2007; 38:2629-30. [PMID: 17098020 DOI: 10.1016/j.transproceed.2006.08.005] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Abstract
The shortage of donor kidneys for renal transplantation is becoming more severe as the gap between the number of patients waiting for renal transplantation and the number of cadaveric organs available continues to widen. Therefore, many centres have started using non-heart-beating (NHB) donors. There was no clear plan for maximal duration of agonal period in Maastricht category NHB donors after withdrawal of treatment in Newcastle. This withdrawal has been audited in retrospect. Our current wait time is now a maximum of 5 hours; however, previously there have been some considerably longer periods. Concern has always been expressed about poor quality with protracted periods. Nonuse in this review of 58 kidneys can be expressed against time: 0 to 2 hours 13%, 2 to 5 hours 33%, and >5 hours 45%. Therefore, though the nonuse rate was significantly different between 0 to 2 hours and >5 hours (P < .05, chi-square), there were 16 transplants performed with kidneys >2 hours and 12 transplanted >5 hours. In conclusion, although good usable kidneys can still be used with protracted withdrawal, there are considerable logistical difficulties with our 5-hour cut-off, which means that one third of potential kidneys will not be utilized.
Collapse
|
90
|
Sohrabi S, Navarro A, Wilson C, Asher J, Sanni A, Wyrley-Birch H, Vijayanand D, Reddy M, Rix D, Jacques B, Manas D, Talbot D. Renal Graft Function After Prolonged Agonal Time in Non–Heart-Beating Donors. Transplant Proc 2006; 38:3400-1. [PMID: 17175284 DOI: 10.1016/j.transproceed.2006.10.080] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/19/2006] [Indexed: 11/17/2022]
Abstract
To deal with the increasing gap between organ demand and supply for kidney transplantation, many centers have started to use non-heart-beating (NHB) donors. When we initiated our program to utilize kidneys from such donors in 1998, we had no protocol for the maximal agonal period. This however was audited in retrospect. Our current wait time is now a maximum of 5 hours. Concern has been expressed in the past about possible deterioration in the quality of the organs with a protracted agonal time. We aimed in this study to examine the effect of prolonging agonal period on the quality of kidneys retrieved from Maastricht category III donors: A total of 40 kidneys were transplanted from 29 category III donors between 1998 and 2004. Eleven kidneys had donor agonal times of >5 hours; the remainder, agonal times <5 hours. Both groups were matched for donor and recipient factors. The mean glomerular filtration rates at 12 months for <5 hours versus >5 hours agonal time were 43.8 +/- 4.4 versus 49.8 +/- 5.8, respectively (P = .24) and at 24 months, 46.83 +/- 8.99 versus 37.67 +/- 3.85, respectively (P = .24). In conclusion, intermediate graft function is comparable to ones with shorter agonal time, although we await long-term results.
Collapse
|
91
|
Yadav J, Reddy M, Rao P, Prasad A. Enantioselective Synthesis of (+)-Sedamine and (-)-Allosedamine. SYNTHESIS-STUTTGART 2006. [DOI: 10.1055/s-2006-950331] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
92
|
Navas TA, Nguyen AN, Hideshima T, Reddy M, Ma JY, Haghnazari E, Henson M, Stebbins EG, Kerr I, O'Young G, Kapoun AM, Chakravarty S, Mavunkel B, Perumattam J, Luedtke G, Dugar S, Medicherla S, Protter AA, Schreiner GF, Anderson KC, Higgins LS. Inhibition of p38alpha MAPK enhances proteasome inhibitor-induced apoptosis of myeloma cells by modulating Hsp27, Bcl-X(L), Mcl-1 and p53 levels in vitro and inhibits tumor growth in vivo. Leukemia 2006; 20:1017-27. [PMID: 16617327 DOI: 10.1038/sj.leu.2404200] [Citation(s) in RCA: 64] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
Abstract
Inhibition of p38 kinase blocks the production of tumor-promoting factors in the multiple myeloma (MM) bone marrow microenvironment. Proteasome inhibitors MG132 and bortezomib have been shown to have direct cytotoxic effects on MM cells. We show that a selective inhibitor of p38alpha, SCIO-469, enhances the ability of MG132 and bortezomib to induce the apoptosis of MM cells. Previously, we showed that p38 inhibition with SCIO-469 enhances MM cytotoxicity of bortezomib by inhibiting the transient expression and phosphorylation of Hsp27, a downstream target of p38. Here we show that continued treatment of MM cells with bortezomib leads to a SCIO-469-enhanced downregulation of Hsp27 and to increased MM apoptosis. Furthermore, we show that p38 inhibition enhances the bortezomib-induced MM apoptosis by upregulation of p53 and downregulation of Bcl-X(L) and Mcl-1. In a mouse xenograft plasmacytoma model of MM, we found that inhibiting p38 augments the effects of bortezomib in decreasing MM tumor growth in vivo. Thus, in addition to its role in suppressing an activated MM microenvironment, co-treatment with a p38 inhibitor, such as SCIO-469, may enhance the cytotoxicity of bortezomib by modulating pro-apoptotic and anti-apoptotic factors in MM cells, suggesting great potential for co-therapy.
Collapse
|
93
|
Gondi CS, Kandhukuri N, Yanamandra N, Reddy M, Reddy E, Rao JS. Regression of pre-established intracranial tumor growth by ON 01910.Na, a selective anticancer agent currently in phase I trials. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.1576] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
1576 Background: Despite considerable progress in the treatment modalities used for brain tumors (surgery, radiation therapy and chemotherapy), local recurrence continues to be an important reason for treatment failure. Since multiple regulatory pathways are defective in these tumor cells, novel approaches must tackle more than one mechanism involved in the process of neoplasia. One approach is to effectively combine anti-tumor agents with anti-angiogenic assault. Onconova has developed agents that fit this profile. ON 01910.Na, an injectable product now undergoing Phase I studies at multiple centers, is a potent inhibitor of mitotic progression. It arrests cancer cells in mitosis by depleting cells of CDC25c and efficiently induces apoptosis in the irreversibly arrested cells. Methods: Here, we have evaluated the invasiveness, angiogenesis, and tumorigenicity of glioblastoma cells in both in vitro and in vivo models after treatment with ON 01910. Results: SNB19 cells treated with ON 01910 were significantly inhibited in migration, invasion, and angiogenesis in in vitro models compared to the control group. After treatment with ON 01910, SNB19 cells showed decreased levels of MMPs, uPA, pAKT and PI3 kinase levels compared to controls. Significantly increased levels of PARP, caspase 3 and caspase 9 were also shown. In addition, there was complete regression of pre-established intracranial tumor growth and angiogenesis in in vivo models. The effect was more significant in relation to invasion, angiogenesis and tumor growth when compared to other drugs such as BCNU and Gleevec. Toxicology studies, where ON 01910 was administered systemically or directly into the brain, demonstrate the safey and tolerability of this agent in animals and ongoing Phase I studies indicate that the agent is well-tolerated at dose levels generating pharmacologically relevant concentration of the drug in circulation. Conclusions: These studies validate the potential usefulness of this compound as a novel therapeutic agent for human glioblastoma. [Table: see text]
Collapse
|
94
|
Giribabu L, Chandrasekharam M, Mohan S, Rao C, Kantam M, Reddy M, Reddy P, Toru T. Highly Efficient One-Pot Synthesis of Metalloporphyrazines under Mild Conditions. Synlett 2006. [DOI: 10.1055/s-2006-944186] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
95
|
Bhagavathula N, Kelley EA, Reddy M, Nerusu KC, Leonard C, Fay K, Chakrabarty S, Varani J. Upregulation of calcium-sensing receptor and mitogen-activated protein kinase signalling in the regulation of growth and differentiation in colon carcinoma. Br J Cancer 2006; 93:1364-71. [PMID: 16278666 PMCID: PMC2361535 DOI: 10.1038/sj.bjc.6602852] [Citation(s) in RCA: 43] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022] Open
Abstract
In the present study, we demonstrate that Ca2+-induced growth inhibition and induction of differentiation in a line of human colon carcinoma cells (CBS) is dependent on mitogen-activated protein (MAP) kinase signaling and is associated with upregulation of extracellular calcium-sensing receptor (CaSR) expression. When CBS cells were grown in Ca2+-free medium and then switched to medium supplemented with 1.4 mM Ca2+, proliferation was reduced and morphologic features of differentiation were expressed. E-cadherin, which was minimally expressed in nonsupplemented medium, was rapidly induced in response to Ca2+ stimulation. Sustained activation of the extracellular signal-regulated kinase (ERK) occured in Ca2+-supplemented medium. When an inhibitor of ERK activation (10 μM U0126) was included in the Ca2+-supplemented culture medium, ERK-activation did not occur. Concomitantly, E-cadherin was not induced, cell proliferation remained high and differentiation was not observed. The same level of Ca2+ supplementation that induced MAP kinase activation also stimulated CaSR upregulation in CBS cells. A clonal isolate of the CBS line that did not upregulate CaSR expression in response to extracellular Ca2+ was isolated from the parent cells. This isolate failed to produce E-cadherin or undergo growth inhibition/induction of differentiation when exposed to Ca2+ in the culture medium. However, ERK-activation occurred as efficiently in this isolate as in parent CBS cells or in a cloned isolate that underwent growth reduction and differentiation in response to Ca2+ stimulation. Together, these data indicate that CaSR upregulation and MAP kinase signalling are both intermediates in the control of colon carcinoma cell growth and differentiation. They appear to function, at least in part, independently of one another.
Collapse
|
96
|
|
97
|
Fronczek FR, Donia M, Reddy M, Rao KV, Peng J, Hamann MT. Hydrogen bonding and absolute configuration in manzamine alkaloids. Acta Crystallogr A 2005. [DOI: 10.1107/s0108767305088276] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
|
98
|
Rao K, Reddy M, Narender M, Nageswar Y. A Facile β-Cyclodextrin-Catalyzed Oxidative Deprotection of tert-Butyldimethylsilyl (TBDMS) Ethers with NBS in Water. SYNTHESIS-STUTTGART 2005. [DOI: 10.1055/s-2005-861808] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
99
|
Reddy M, Faust R, Secord E, Pansare M. Bronchus suis masquerading as asthma. J Allergy Clin Immunol 2005. [DOI: 10.1016/j.jaci.2004.12.052] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
100
|
Rastogi D, Kairam J, Reddy M. Increased sensitization to indoor versus outdoor allergens in inner-city asthmatic children. J Allergy Clin Immunol 2005. [DOI: 10.1016/j.jaci.2004.12.291] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|